Psilocybin

ClinicalAugust 18, 2026

Psilocybin trial initiated to prevent chemotherapy-induced neuropathy in cancer patients

A clinical trial (NCT07227909) has been initiated to evaluate the efficacy of psilocybin in preventing chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing chemotherapy for breast and colorectal cancer. The trial is sponsored by M.D.

ClinicalAugust 14, 2026

Psilocybin fMRI Study Initiated for Major Depressive Disorder

An open-label fMRI study is assessing the effects of a single dose of psilocybin on rumination in major depressive disorder.

ClinicalJuly 6, 2026

Psilocybin Therapy Shows Promise for Depression in Parkinson's Disease

A clinical trial is underway to evaluate the efficacy of psilocybin therapy in patients with Parkinson's Disease and depression.

Recent signals(4)

Psilocybin trial initiated to prevent chemotherapy-induced neuropathy in cancer patients

Psilocybin fMRI Study Initiated for Major Depressive Disorder

Psilocybin Therapy Shows Promise for Depression in Parkinson's Disease

Psilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression

Upcoming milestones

Related catalysts(1)

— Psilocybin

Indications

Therapeutic areas

Get signals before the market moves